Books > Medicine > Clinical & internal medicine > Rheumatology
|
Buy Now
Azapropazone - 20 years of clinical use (Paperback, Softcover reprint of the original 1st ed. 1989)
Loot Price: R1,474
Discovery Miles 14 740
|
|
Azapropazone - 20 years of clinical use (Paperback, Softcover reprint of the original 1st ed. 1989)
Expected to ship within 10 - 15 working days
|
Azapropazone is a chemically unique non-steroidal anti-inflammatory
drug (benzotriazine oxide) which has found successful clinical
applications in the therapy of a wide variety of arthritic
conditions. This book summarizes the progress and critically
reviews the clinical use and experimental studies since its
introduction 20 years ago. Several studies focus on the
physiochemical, pharmacological and toxico logical properties of
this drug. The studies suggest that it has some unique properties
compared with other non-steroidal anti-inflammatory drugs. Among
these the novel observations are that azapropazone inhibits several
non-prostaglandin-related leucocyte functions, especially
superoxide anion production. These serve as a basis for
investigations which are reviewed showing the potential for the
drug to prevent the pathological consequencies of myocardial
ischaemia. The preparation of this book would not have been
possible without the cooperation of the four companies who produce,
market, or have research involvement with azapropazone, namely
Siegfried AG (the manufacturers of the drug), A.H. Robins (U.K.)
Co. Ltd., Robapharm AG (Switzerland) and E. . duPont de Nemours
(U.S.A., Switzerland and F.R.G.)."
General
Is the information for this product incomplete, wrong or inappropriate?
Let us know about it.
Does this product have an incorrect or missing image?
Send us a new image.
Is this product missing categories?
Add more categories.
Review This Product
No reviews yet - be the first to create one!
|
You might also like..
|
Email address subscribed successfully.
A activation email has been sent to you.
Please click the link in that email to activate your subscription.